Description
What this story covers
ResMed's Q2 FY2025 10-Q reveals 10 percent revenue growth to 1.282 billion dollars, driven by sleep health devices and software. Gross margins improved to 58.6 percent, operating income up 52 percent to 417 million dollars, net income 65 percent higher at 345 million dollars. Strong liquidity, low debt, and 2030 strategy focus on connected care amid rising sleep disorder demand.
Story snapshot
CompanyResMed Inc.
TickerRMD
VariantStandard detailed
Duration12:44
Filing type10-Q
PeriodQ2 2025
IndustryHealthcare & Pharmaceuticals
Accession0000943819-25-000004
Full Story Script
Content not available for this story.
